Media headlines about NuCana (NASDAQ:NCNA) have trended somewhat negative on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuCana earned a media sentiment score of -0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4064362550891 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several research analysts have recently issued reports on NCNA shares. Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Thursday, January 18th. Cowen assumed coverage on NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. William Blair assumed coverage on NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. Citigroup assumed coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $23.00 price target for the company. Finally, Jefferies Group assumed coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 price target for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.00.
NuCana (NASDAQ NCNA) opened at $19.87 on Monday. NuCana has a 12-month low of $9.32 and a 12-month high of $29.75.
ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/19/nucana-ncna-given-coverage-optimism-rating-of-0-17.html.
NuCana Company Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.